DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) Global Clinical Trials Review, H1, 2013" report to their offering.
'Attention Deficit Hyperactivity Disorder (ADHD) Global Clinical Trials Review, H1, 2013' provides data on the Attention Deficit Hyperactivity Disorder (ADHD) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Attention Deficit Hyperactivity Disorder (ADHD). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Attention Deficit Hyperactivity Disorder (ADHD).
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)
Top Companies Participating in Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials
- AbbVie Inc.
- Alcobra Ltd
- Alza Corporation
- AstraZeneca PLC
- Cephalon, Inc.
- Eisai Inc.
- Eli Lilly and Company
- Johnson & Johnson
- Medice Arzneimittel Putter GmbH & Co. KG
- Merck & Co., Inc.
- New River Pharmaceuticals, Inc.
- Novartis AG
- Noven Pharmaceuticals, Inc.
- Ortho-McNeil-Janssen Pharmaceuticals, Inc.
- Pfizer Inc.
- Shire Plc
- Sunovion Pharmaceuticals Inc.
- Supernus Pharmaceuticals, Inc.
- Teva Pharmaceuticals USA, Inc.
- Yuyu Pharma, Inc.
For more information visit Research and Markets
